Survodutide, as a dual GLP-1/glucagon receptor agonist, further supports the plausibility of glucagon receptor activation as a useful therapeutic component when paired with GLP-1 signaling
Giri S, Chandra P (2025) Modulation of neuropathological pathways by bioactive peptides and proteins/polypeptides: targeting oxidative stress in neurodegenerative diseases
When is shipping free
81,82 Additionally, EX-BID has been shown to increase adiponectin levels, potentially offering cardiovascular benefits
Current clinical data indicate that GLP-1R agonists reduce BP in diabetic patients (92) and the antihypertensive effect can also be observed in Dahl salt-sensitive rats (93), in Ang II -induced hypertension rats (91) and SHRs rats (94)
This difference may stem from methodological limitations inherent in the cross-sectional observation design, thus longitudinal studies are needed to elucidate temporal relationships and validate these findings